Macro and Strategy Research - The US economy shows strong internal momentum with a 0.3% month-on-month increase in personal consumption expenditures adjusted for inflation in November 2025, marking the highest growth rate since the second half of 2025 [2] - In Europe, inflation dropped below 2% year-on-year in December 2025, indicating easing pressure, supported by labor costs and year-end consumption [3] - Domestic economic growth in China for 2025 is expected to meet targets despite a slowdown in the fourth quarter, with net exports providing structural support in early 2026 [3] Fixed Income Research - The bond market continues to show signs of recovery, with mid- to long-term bonds performing well, driven by a strong equity market and manageable bank liability pressures [5][7] - The issuance of special bonds increased significantly, with a total of 56 bonds issued, amounting to 619.1 billion yuan during the reporting period [7] - The overall bond market is characterized by a recovery trend, with the yield on 7-year government bonds declining the most [7] Industry Research - Nine departments in China have issued opinions to promote high-quality development in the pharmaceutical retail industry, indicating potential benefits for leading chain pharmacies and an expected operational turning point [10][12] - The SW pharmaceutical industry index shows a price-to-earnings ratio of 52.01, with a valuation premium of 266% relative to the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring segments like small nucleic acids [12]

Group 1 - The macro environment shows easing external pressures from US-Europe relations, with a rebound in the Fed's interest rate cut trades and stable domestic macro data, alongside improvements in real estate high-frequency indicators [1] - Foreign and southbound capital continue to flow in, with public fund positions in Hong Kong stocks dropping to 23% in Q4, significantly reducing potential selling pressure [1] - The sentiment index has returned to a neutral range, with bullish expectations increasing, indicating a continued potential for a rebound in the first quarter [1] Group 2 - Focus on the AI chain (semiconductors, software) and innovative pharmaceuticals, while gradually accumulating quality consumer leaders and overweighting the upstream of the cyclical and power chains [1]

Group 1 - The QDII funds have shown impressive performance since 2025, with an average net value increase of 27.9%, particularly driven by funds heavily invested in Hong Kong innovative pharmaceuticals [2] - Notable funds such as Huatai-PB Korea Semiconductor ETF and E Fund Global Growth Select Mixed A have seen net value increases of 127.55% and 102.91% respectively, with several other funds also exceeding 80% growth [2] - The top holdings of these high-performing funds predominantly include Hong Kong innovative pharmaceutical stocks, with examples like Kelun-Botai Biotech and Innovent Biologics among the top five holdings of Huatai-PB Hong Kong Advantage Select Mixed A [2] Group 2 - The technology sector is also a key focus for many high-performing products, with E Fund Global Growth Select Mixed A holding major global tech stocks such as TSMC and Google-A among its top ten holdings [3] - Fund managers express optimism for the future of the innovative pharmaceutical and technology sectors, citing a recent phase of adjustment in the innovative drug industry as a temporary market sentiment issue rather than a fundamental change [4][5] - The innovative drug sector's valuation has become attractive, with expectations of upward potential, and the industry is anticipated to show resilience and technological attributes over the next 2 to 3 years [5] Group 3 - The pharmaceutical industry is expected to see positive changes in 2026, with contract development organizations (CXO) gaining confidence from solid data, and new technologies like artificial intelligence and brain-machine interfaces opening new application scenarios [5] - The semiconductor sector, particularly in storage, is projected to continue its cycle, with local market trends favoring leading storage manufacturers and potential IPOs supporting capacity expansion [6]

Investment Rating - The report suggests a positive outlook for the innovative drug sector, indicating it will continue to be a core investment direction in 2026 due to the maturation of the industry chain and normalization of medical insurance negotiations [4]. Core Insights - The public fund's pharmaceutical holdings decreased to 8.11% in Q4 2025, down by 1.66 percentage points (pp) from the previous quarter. Excluding actively managed pharmaceutical funds, the holdings dropped to 3.90%, a decrease of 1.36pp [11][12]. - The innovative drug ETF reached a scale of 100.62 billion yuan in Q4, accounting for 13.11% of the pharmaceutical fund, which is a slight decrease of 1.35pp [13][15]. - The CXO sector saw a decline in holdings due to geopolitical disturbances, while the medical device sector benefited from innovations like brain-computer interfaces and surgical robots, leading to an increase in holdings [14][17]. - The report highlights the acquisition of PART by GSK for $2.2 billion to strengthen its position in the IgE antibody market, with the core product Ozureprubart showing significant market potential [2][31]. - The oral weight loss drug Wegovy has shown strong early commercial progress, with retail prescriptions reaching approximately 3,071 in the first four days post-launch, nearly three times that of its competitor Zepbound [2][31]. Summary by Sections Pharmaceutical Sector - The report indicates a significant decrease in public fund holdings in the pharmaceutical sector, with a noted resilience in the innovative drug segment [11][14]. - The report emphasizes the importance of focusing on leading companies with core pipeline competitiveness and global layout capabilities for investment [4]. Medical Devices - The introduction of new pricing guidelines for auxiliary medical services is expected to accelerate the adoption of innovative products in the medical device sector [3][17]. - The report suggests monitoring domestic leading companies in this sector for increasing product penetration [3]. Drugstores - The report discusses the potential for leading drugstore companies to increase market share, supported by recent government policies promoting high-quality development in the retail pharmaceutical industry [3][17]. - Specific companies like Yifeng Pharmacy and Dazhenglin are highlighted as having low valuations and significant cost reduction achievements [3]. CXO and Pharmaceutical Supply Chain - Several CXO companies have released optimistic earnings forecasts for 2025, indicating a clear upward trend in industry prosperity [2][31]. - The report recommends active investment in this sector due to the positive signals regarding industry growth [2][31].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry but emphasizes a positive outlook on various segments within the industry, particularly innovative drugs and medical devices [9][10]. Core Insights - The pharmaceutical industry is transitioning from a quantity-driven logic to a quality-driven logic, focusing on differentiated products and internationalization by 2025 [9]. - There is a notable shift in funding from active to passive medical funds, indicating a low allocation status in the pharmaceutical sector, which is expected to change as passive funds become a significant part of the investment landscape [16][17]. - The report outlines a structured approach to ETF investment in the pharmaceutical sector, emphasizing a dynamic combination of broad-based and targeted strategies to balance returns and risks [27]. Summary by Sections Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 sectors [6]. - The top-performing stocks included *ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, while the worst performers were Kaiyin Technology and Aidi Pharmaceutical [6]. Innovative Drugs - The report highlights a positive outlook for domestic innovative drugs, suggesting a focus on companies that can deliver profits, such as BeiGene, Innovent Biologics, and others [9]. Medical Devices - The medical device sector is expected to see a recovery in bidding volumes for imaging equipment by 2025, with a focus on companies like Mindray and United Imaging [9]. - The home medical device market is also anticipated to grow due to supportive policies and accelerated international expansion [9]. Innovation Chain (CXO + Life Science Services) - The report indicates a potential recovery in overseas investment and financing, with domestic financing expected to stabilize, marking the beginning of a new wave of innovation [9]. Pharmaceutical Industry - The report suggests that the specialty API sector may see cost improvements, leading to a new growth cycle, with companies like Tonghua Dongbao and Huahai Pharmaceutical highlighted for their potential [9]. Traditional Chinese Medicine - The report discusses the expected growth in the basic drug market and the impact of state-owned enterprise reforms on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [11]. Pharmacy Sector - The report expresses optimism about the pharmacy sector due to the acceleration of prescription outflow and the optimization of competitive dynamics, recommending companies like YaoXing and YiFeng Pharmacy [11]. Medical Services - The report notes that anti-corruption measures and centralized procurement are improving the market environment for private medical services, with recommendations for companies like Huashan Medical and Aier Eye Hospital [11]. Blood Products - The report anticipates a favorable long-term growth path for the blood products industry, with companies like TianTan Biological and Boya Biological expected to benefit from increased demand and supply elasticity [11].

Core Viewpoint - The article discusses the investment framework for the pharmaceutical industry ETF in 2026, emphasizing a dual-driven approach of demand and innovation to navigate the market recovery and differentiation after a prolonged bear market since 2021 [29]. Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 primary industries [9]. - The top ten stocks by increase this week included ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, with gains ranging from 6% to 70.38% [9]. - The bottom ten stocks by decrease included Kain Technology and Aidi Pharmaceutical, with declines of up to 45% [9]. Industry and Stock Events - The article highlights a shift in funding from active to passive management in the pharmaceutical sector, with passive funds becoming a significant part of the long-term funding structure [18]. - The article notes that the innovation drug sector is expected to see a transition from quantity to quality, focusing on differentiated products and internationalization by 2025 [12]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from policies promoting home medical devices and accelerated overseas expansion [12]. - The article discusses the favorable conditions for the blood products industry, with relaxed approval for plasma stations and a clear growth path for the industry during the 14th Five-Year Plan period [13]. Investment Strategy - The article proposes a dynamic ETF configuration framework for the pharmaceutical sector, categorized into three layers: a core base of broad-based ETFs, a dual-driven layer focusing on innovative drugs and medical devices, and a defensive layer using traditional Chinese medicine and overseas biotech [22]. - The article emphasizes the importance of a systematic approach to ETF selection, considering liquidity, tracking quality, and cost [24]. - It suggests that the pharmaceutical sector is entering a new growth cycle driven by rigid demand and continuous innovation, necessitating a more structured and rhythmic ETF combination strategy [22].

Core Viewpoint - The efficiency of Chinese innovative pharmaceutical companies in research and development is putting pressure on American firms, leading to a shift in strategy where multinational companies are cutting internal R&D budgets to invest in Chinese companies' pipelines [1][7]. Group 1: JPM Conference Insights - The 2026 JPM conference saw a significant presence of Chinese innovative pharmaceutical executives and investors, reflecting a positive outlook compared to previous years, with multinational companies openly expressing interest in Chinese assets [2][4]. - Chinese companies are no longer satisfied with merely licensing patents; they seek deeper involvement in clinical development and commercialization in international markets [3][10]. - The FDA's officials acknowledged the R&D efficiency of Chinese companies and suggested using AI to improve approval processes, indicating a more collaborative approach rather than a protectionist stance [3][6]. Group 2: Market Trends and Stock Performance - Following a surge in business development (BD) transactions in 2025, the stock prices of Chinese innovative pharmaceutical companies saw a significant increase, but there was a market correction starting in September 2025, with the Hang Seng Innovation Drug Index dropping over 20% by January 2026 [3][12]. - The participation of seven Chinese pharmaceutical companies in the main stage of JPM is a sign of increasing recognition and influence in the international market [12]. Group 3: Strategic Shifts in Collaboration - There is a growing trend among Chinese pharmaceutical companies to engage in deeper collaborations, such as the NewCo model, which allows for shared operations and deeper partnerships with American firms [10][11]. - American biotech companies are considering establishing NewCo in China to leverage the country's advantages in R&D efficiency and cost [11]. Group 4: Competitive Landscape and Future Outlook - The competitive landscape is shifting, with Chinese companies focusing on unmet clinical needs and exploring new therapeutic areas beyond traditional targets, such as liver diseases [11]. - Multinational companies are actively seeking new opportunities due to impending patent cliffs, with significant interest in mergers and acquisitions to bolster their pipelines [14][15]. - PwC's report indicates that patent expirations could risk $47 billion in drug sales over the next four years, prompting increased acquisition activities in the pharmaceutical sector [16].

Core Insights - The 2026 JPM conference showcased a positive outlook for Chinese innovative pharmaceutical companies, with significant interest from multinational corporations in collaboration opportunities [2][3][4] - Chinese companies are shifting from merely licensing patents to deeper involvement in clinical development and commercialization in international markets [3][8] - The FDA's stance at JPM was relatively moderate, acknowledging the R&D efficiency of Chinese companies and suggesting improvements in approval processes using AI [3][6] Group 1: Conference Overview - The JPM conference, held in San Francisco, attracted numerous founders, executives, and investors from Chinese innovative pharmaceutical companies, indicating a vibrant atmosphere compared to previous years [2][5] - The event has evolved from a small gathering to a major industry benchmark, with participation from nearly all multinational pharmaceutical companies [5][10] - The number of attendees increased significantly in 2026, reflecting a more optimistic market sentiment compared to the previous year [5][10] Group 2: Market Trends - The Chinese innovative drug sector experienced a substantial stock price increase from March to August 2025, driven by business development (BD) transactions and foreign capital inflow, but faced a market correction afterward [4][11] - The interest in Chinese assets is growing, with many multinational companies expressing intentions for mergers and acquisitions (M&A) and BD transactions [11][12] - The trend of Chinese companies seeking deeper engagement in global markets is evident, moving beyond simple patent licensing to collaborative operational models [8][9] Group 3: Regulatory Environment - FDA officials at JPM highlighted the efficiency of Chinese clinical trials, with China completing Phase I trials in four weeks compared to much longer timelines in the U.S. [6][12] - The FDA's comments suggested a focus on optimizing clinical trial approval processes rather than emphasizing protectionist policies [5][6] Group 4: Future Outlook - The absence of major transactions at JPM 2026 was noted, but many multinational companies expressed a willingness to explore significant deals in the near future [11][12] - The upcoming expiration of patents for several blockbuster drugs is expected to drive increased M&A activity as companies seek to replenish their pipelines [12][13] - The trend of U.S. biotech firms considering establishing operations in China to leverage R&D efficiencies is emerging, indicating a shift in cross-border collaboration dynamics [10][11]

Market Overview - A-shares saw a collective rise on January 23, with the three major indices increasing and total trading volume exceeding 3 trillion yuan, up by 401.7 billion yuan from the previous day [1] - The photovoltaic sector surged, driven by Elon Musk's support for space photovoltaics, leading to a wave of limit-up stocks, including Longi Green Energy [1] - The commercial aerospace concept continued to soar, with ETFs related to general aviation and military industries also experiencing significant gains [1] Sector Performance - The photovoltaic sector saw a strong performance, with the only green energy ETF tracking the green energy index rising by 3.68% [1] - The general aviation ETF rose by 3.67%, marking a strong three-day rally, supported by multiple favorable catalysts [5][9] - The non-ferrous metals sector also performed well, with the non-ferrous ETF increasing by 3.37%, breaking through its listing high and attracting significant net subscriptions [1][9] AI and Technology - Nvidia's CEO compared AI to a "five-layer cake," emphasizing the importance of AI applications, which led to a 2.02% increase in the domestic AI ETF [2] - The entrepreneurial AI ETF saw a rapid increase in scale, growing from over 50 billion yuan to 60 billion yuan in just three trading days, becoming the largest AI ETF in the dual innovation track [2][20] Future Outlook - Guosen Securities maintains a bullish outlook for A-shares, citing favorable macroeconomic policies and expected inflows from long-term funds [4] - Huaxi Securities suggests focusing on three main investment lines: technology sector expansion, beneficiaries of "anti-involution" policies, and companies with high earnings growth forecasts [4] Commercial Aerospace Developments - The commercial aerospace and satellite navigation sectors are experiencing a resurgence, with significant stock price increases for companies like Ruichuang Micro-Nano and China Satellite [5][7] - The upcoming "Star Computing and Intelligent Connection" seminar is expected to further stimulate interest in the commercial aerospace market [7] Precious Metals - International gold prices have surged, reaching historical highs, driven by geopolitical risks and increased demand for safe-haven assets [11] - The non-ferrous metals sector is expected to continue its strong performance, supported by macroeconomic policies and structural changes in supply and demand [11]

Group 1 - The overall positioning of public funds has become clearer with the completion of the 2025 Q4 reports, showing a notable shift towards cyclical and small-cap growth stocks, while the allocation to Hong Kong stocks has decreased significantly from 19.26% to 16.23% [1] - The decline in the strategic position of Hong Kong stocks within active equity funds contrasts with the upward trend in the A-share market, raising concerns about the future performance of Hong Kong stocks [1] - The A-share market has shown a strong growth style, with significant thematic investment in sectors like commercial aerospace and artificial intelligence hardware, which are less represented in the Hong Kong market [2] Group 2 - Hong Kong stocks are facing dual pressures on liquidity, both from external factors and southbound capital, making them more sensitive to liquidity changes compared to A-shares [3] - Despite a record inflow of 1.4 trillion RMB from southbound capital in 2025, the pace has slowed significantly in Q4, with daily average inflows dropping to 10.9 million HKD in December [3] - The IPO market in Hong Kong has thrived, with 117 IPOs raising 285.9 billion HKD in 2025, marking a return to the top globally, but a potential wave of lock-up expirations could pose challenges [4][5] Group 3 - The upcoming lock-up expirations for major companies listed in the first half of 2025 could lead to significant selling pressure, with an estimated 120 billion HKD in potential unlocks by December [4] - Historical patterns indicate that lock-up expirations have coincided with declines in the Hong Kong market, although strong-performing companies may still attract new investments [5] - The market's current dynamics suggest that while there may be selling pressure from lock-up expirations, the presence of new buying forces could offset this impact [5]